HK1200812A1 - Rod -like hepatitis c virus inhibitors containing the fragement 2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl amine 2-[4-(-4-)-1h--2-]-1- - Google Patents
Rod -like hepatitis c virus inhibitors containing the fragement 2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl amine 2-[4-(-4-)-1h--2-]-1-Info
- Publication number
- HK1200812A1 HK1200812A1 HK15101128.6A HK15101128A HK1200812A1 HK 1200812 A1 HK1200812 A1 HK 1200812A1 HK 15101128 A HK15101128 A HK 15101128A HK 1200812 A1 HK1200812 A1 HK 1200812A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- carbonlymethyl
- fragement
- imidazo
- pyrrolidine
- hepatitis
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 3
- 241000711549 Hepacivirus C Species 0.000 title 1
- 150000001412 amines Chemical class 0.000 title 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555056P | 2011-11-03 | 2011-11-03 | |
| US201261600089P | 2012-02-17 | 2012-02-17 | |
| US201261637961P | 2012-04-25 | 2012-04-25 | |
| PCT/US2012/063181 WO2013067267A1 (en) | 2011-11-03 | 2012-11-02 | Rod -like hepatitis c virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1200812A1 true HK1200812A1 (en) | 2015-08-14 |
Family
ID=47146777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15101128.6A HK1200812A1 (en) | 2011-11-03 | 2015-02-03 | Rod -like hepatitis c virus inhibitors containing the fragement 2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl amine 2-[4-(-4-)-1h--2-]-1- |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9212168B2 (es) |
| EP (1) | EP2773634B1 (es) |
| JP (2) | JP6082747B2 (es) |
| KR (1) | KR20140091036A (es) |
| CN (1) | CN103946220B (es) |
| AR (1) | AR088630A1 (es) |
| AU (1) | AU2012332358B2 (es) |
| BR (1) | BR112014010401A8 (es) |
| CA (1) | CA2852700A1 (es) |
| CL (1) | CL2014001110A1 (es) |
| CO (1) | CO6940424A2 (es) |
| HK (1) | HK1200812A1 (es) |
| IL (1) | IL232042A (es) |
| MX (1) | MX347692B (es) |
| RU (1) | RU2625787C2 (es) |
| SG (1) | SG11201401891RA (es) |
| TW (1) | TWI577672B (es) |
| WO (1) | WO2013067267A1 (es) |
| ZA (1) | ZA201403198B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103189371B (zh) | 2010-11-04 | 2015-04-01 | 施万生物制药研发Ip有限责任公司 | 丙型肝炎病毒抑制剂 |
| GEP20166554B (en) | 2012-04-25 | 2016-10-10 | Takeda Pharmaceuticals Co | Nitrogenated heterocyclic compound |
| WO2013163270A1 (en) * | 2012-04-25 | 2013-10-31 | Theravance, Inc. | Hepatitis c virus inhibitors |
| US9206159B2 (en) | 2012-04-25 | 2015-12-08 | Theravance Biopharma R&D Ip, Llc | Piperazine-piperidine compounds as hepatitis C virus inhibitors |
| US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
| JP6280912B2 (ja) | 2013-03-14 | 2018-02-14 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3018123B1 (en) | 2013-07-03 | 2023-05-10 | Takeda Pharmaceutical Company Limited | Amide compound |
| WO2015002231A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | 複素環化合物 |
| CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
| CN106256819B (zh) * | 2015-06-19 | 2019-07-09 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| WO2016202232A1 (zh) * | 2015-06-19 | 2016-12-22 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| WO2017015439A1 (en) * | 2015-07-21 | 2017-01-26 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a hepatitis c virus inhibitor |
| WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
| CN107501155A (zh) * | 2017-09-19 | 2017-12-22 | 上海泓博智源医药股份有限公司 | 一种抗病毒药物中间体的制备方法 |
| CN112679407B (zh) * | 2021-03-17 | 2021-06-04 | 南京桦冠生物技术有限公司 | 一种手性5-取代脯氨酸类化合物的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2299207C2 (ru) * | 2001-08-30 | 2007-05-20 | Кова Ко., Лтд. | Соединения циклического амина |
| US6867221B2 (en) | 2001-08-30 | 2005-03-15 | Kowa Co., Ltd. | Cyclic amine compounds and pharmaceutical composition containing the same |
| GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| JP2009508835A (ja) | 2005-09-16 | 2009-03-05 | アロー セラピューティクス リミテッド | ビフェニル誘導体及びｃ型肝炎の治療におけるその使用 |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8303944B2 (en) | 2006-08-11 | 2012-11-06 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN101558059B (zh) * | 2006-08-11 | 2014-12-03 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| DE102009005746A1 (de) * | 2009-01-23 | 2010-07-29 | Merck Patent Gmbh | Materialien für organische Elektrolumineszenzvorrichtungen |
| UY32462A (es) | 2009-02-23 | 2010-09-30 | Arrow Therapeutics Ltd | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI629981B (zh) | 2009-05-13 | 2018-07-21 | 基利法瑪席特有限責任公司 | 抗病毒化合物 |
| SG178952A1 (en) | 2009-09-04 | 2012-04-27 | Glaxosmithkline Llc | Chemical compounds |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2512480A4 (en) | 2009-12-14 | 2013-05-15 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2013515746A (ja) | 2009-12-24 | 2013-05-09 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症の治療又は予防のための類似体 |
| WO2011091446A1 (en) | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| WO2011153396A1 (en) | 2010-06-04 | 2011-12-08 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CA2809261A1 (en) | 2010-08-26 | 2012-03-01 | Rfs Pharma, Llc | Potent and selective inhibitors of hepatitis c virus |
| WO2012048421A1 (en) | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CN103189371B (zh) * | 2010-11-04 | 2015-04-01 | 施万生物制药研发Ip有限责任公司 | 丙型肝炎病毒抑制剂 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2012
- 2012-11-02 TW TW101140863A patent/TWI577672B/zh not_active IP Right Cessation
- 2012-11-02 BR BR112014010401A patent/BR112014010401A8/pt not_active IP Right Cessation
- 2012-11-02 AU AU2012332358A patent/AU2012332358B2/en not_active Ceased
- 2012-11-02 RU RU2014122340A patent/RU2625787C2/ru not_active IP Right Cessation
- 2012-11-02 CA CA2852700A patent/CA2852700A1/en not_active Abandoned
- 2012-11-02 JP JP2014540112A patent/JP6082747B2/ja not_active Expired - Fee Related
- 2012-11-02 CN CN201280054361.3A patent/CN103946220B/zh not_active Expired - Fee Related
- 2012-11-02 US US13/667,197 patent/US9212168B2/en not_active Expired - Fee Related
- 2012-11-02 MX MX2014005342A patent/MX347692B/es active IP Right Grant
- 2012-11-02 KR KR1020147014928A patent/KR20140091036A/ko not_active Application Discontinuation
- 2012-11-02 WO PCT/US2012/063181 patent/WO2013067267A1/en active Application Filing
- 2012-11-02 AR ARP120104114A patent/AR088630A1/es unknown
- 2012-11-02 SG SG11201401891RA patent/SG11201401891RA/en unknown
- 2012-11-02 EP EP12783835.7A patent/EP2773634B1/en active Active
-
2014
- 2014-04-09 IL IL232042A patent/IL232042A/en not_active IP Right Cessation
- 2014-04-28 CO CO14090226A patent/CO6940424A2/es active IP Right Grant
- 2014-04-29 CL CL2014001110A patent/CL2014001110A1/es unknown
- 2014-05-02 ZA ZA2014/03198A patent/ZA201403198B/en unknown
-
2015
- 2015-02-03 HK HK15101128.6A patent/HK1200812A1/xx unknown
- 2015-10-15 US US14/883,856 patent/US9669027B2/en not_active Expired - Fee Related
-
2016
- 2016-12-06 JP JP2016236386A patent/JP2017048248A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI577672B (zh) | 2017-04-11 |
| CN103946220B (zh) | 2017-12-22 |
| BR112014010401A2 (pt) | 2017-04-25 |
| RU2014122340A (ru) | 2015-12-10 |
| SG11201401891RA (en) | 2014-05-29 |
| IL232042A (en) | 2017-07-31 |
| AR088630A1 (es) | 2014-06-25 |
| AU2012332358A1 (en) | 2014-05-29 |
| WO2013067267A1 (en) | 2013-05-10 |
| CL2014001110A1 (es) | 2014-08-22 |
| TW201326156A (zh) | 2013-07-01 |
| RU2625787C2 (ru) | 2017-07-19 |
| JP2014532716A (ja) | 2014-12-08 |
| KR20140091036A (ko) | 2014-07-18 |
| JP2017048248A (ja) | 2017-03-09 |
| ZA201403198B (en) | 2017-04-26 |
| CA2852700A1 (en) | 2013-05-10 |
| US9669027B2 (en) | 2017-06-06 |
| US20160038483A1 (en) | 2016-02-11 |
| JP6082747B2 (ja) | 2017-02-15 |
| EP2773634A1 (en) | 2014-09-10 |
| IL232042A0 (en) | 2014-05-28 |
| BR112014010401A8 (pt) | 2017-12-19 |
| MX347692B (es) | 2017-05-09 |
| NZ623846A (en) | 2016-07-29 |
| US9212168B2 (en) | 2015-12-15 |
| MX2014005342A (es) | 2014-08-08 |
| CO6940424A2 (es) | 2014-05-09 |
| US20130115194A1 (en) | 2013-05-09 |
| CN103946220A (zh) | 2014-07-23 |
| EP2773634B1 (en) | 2018-06-06 |
| AU2012332358B2 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200812A1 (en) | Rod -like hepatitis c virus inhibitors containing the fragement 2- [4- (bi phenyl - 4 - yl) - 1h - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl amine 2-[4-(-4-)-1h--2-]-1- | |
| DK3686194T3 (da) | 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser | |
| IL221033A0 (en) | Hepatitis c virus inhibitors | |
| EP2575819A4 (en) | INHIBITORS OF HEPATITIS C VIRUS | |
| ZA201306720B (en) | Hepatitis c virus inhibitors | |
| EP2528926A4 (en) | HEPATITIS C INHIBITOR COMPOUNDS | |
| HK1191935A1 (en) | Spiro compounds as hepatitis c virus inhibitors | |
| IL224298A (en) | Hepatitis virus inhibitors c | |
| IL229270A0 (en) | Hepatitis c virus inhibitors | |
| EP2759533A4 (en) | CONDENSED HETEROCYCLIC COMPOUND | |
| EP2603080A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| EP2768517A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| ZA201309356B (en) | Hepatitis c virus inhibitors | |
| HK1212332A1 (en) | Hepatitis c virus inhibitors | |
| EP2748160A4 (en) | INHIBITORY COMPOUNDS OF HEPATITIS C | |
| EP2687529A4 (en) | CONDENSED HETEROCYCLIC COMPOUND | |
| PL2850075T3 (pl) | Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c | |
| EP2748167A4 (en) | INHIBITORY COMPOUNDS OF HEPATITIS C | |
| GB201102024D0 (en) | Novel heterocyclic compounds 3 | |
| GB201101823D0 (en) | Novel heterocyclic compounds 4 | |
| GB201101822D0 (en) | Novel heterocyclic compounds 2 |